A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis
Year: 2021
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Journal of Hepatology
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3128716033
